small molecule

NUZYRA

OMADACYCLINE TOSYLATE

Loss of exclusivityOctober 2037latest FDA-listed patent expiry

CompanyParatek Pharmaceuticals →View the full company profile on CliffBio

Drug detail

Brand name	NUZYRA
Active ingredient	OMADACYCLINE TOSYLATE
Strength	EQ 100MG BASE/VIAL
Dosage form	POWDER
Route	INTRAVENOUS
Modality	Small molecule
FDA approval	October 2018
Marketing status	RX

Listed patents

Patent	Expires	Type
10383884	October 2037	use U-2576
10835542	October 2037	use U-2576
10124014	March 2029	use U-2449
9724358	March 2029	use U-1569
9265740	March 2029	product

Regulatory exclusivity

Code	Expires
GAIN	October 2028
NCE	October 2023

Source: FDA Orange Book, layered on the CliffBio company graph. Cliff dates are the latest FDA-listed patent expiry; estimates are projections, not legal advice.

Drug detail

Listed patents

Regulatory exclusivity

More from Paratek Pharmaceuticals